Floatz logo

Mb-Cart2019.1

CAR T Cell Therapy

Miltenyi Biomedicine GmbHPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the CAR T Cell Therapy cohort.

Asset / SponsorPhaseRating
HUMAN PERIPHERAL BLOOD LEUKOCYTES
The First Affiliated Hospital of Soochow University
Phase 2B
Anti-Cd19/Cd22 Car-T Cells
The First Affiliated Hospital of Soochow University
Phase 2B
cd33-car-t cell infusion
Qi deng
Phase 1CC
cd19/baff-r in vivo car-t cell intravenous infusion
Qi deng
Phase 1CC

Same molecule, other indications

Mb-Cart2019.1 is also rated in:

diffuse large B-cell lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
46 / 100
View asset →
multiple sclerosisDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →